Drug Profile
CTX 110
Alternative Names: Anti-CD19+ CAR-T cells - CRISPR Therapeutics; CTX 101 - CRISPR Therapeutics; CTX110Latest Information Update: 16 Dec 2022
Price :
$50
*
At a glance
- Originator CRISPR Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II B-cell lymphoma; Non-Hodgkin's lymphoma